Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity

US5837293A · kind A · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Rene de Waal Malefyt · Sunnyvale, US
• Maureen Howard · Los Altos Hills, US
• Di-Hwei Hsu · Palo Alto, US
• Hiroshi Ishida · Oyama, JP
• Anne O'Garra · Palo Alto, US
• Hergen Spits · Amsterdam, NL
• Albert Zlotnik · Palo Alto, US

Key dates

• Filing date: Jun 7, 1995
• Grant date: Nov 17, 1998
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.